Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
158 hedge funds and large institutions have $2.4B invested in Turning Point Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 63 increasing their positions, 29 reducing their positions, and 10 closing their positions.
390% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 10
117% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 29
80% more capital invested
Capital invested by funds: $1.33B → $2.4B (+$1.07B)
33% more funds holding
Funds holding: 119 → 158 (+39)
0% more call options, than puts
Call options by funds: $6K | Put options by funds: $6K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$45M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.1M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$33.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.4M |
| 2 |
DM
Deerfield Management
New York
|
-$13M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$10.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.36M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
-$7.16M |
TPTX Hedge Fund Activity: Q2 2020 in Review
158 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q2 2020, worth a combined $2.4B — up 80% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new TPTX positions and 10 closed out — a net gain of 39 holders — while 63 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $45M. The largest seller was Cormorant Asset Management, cutting an estimated $18.4M.
- 158 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q2 2020, up from 119 in Q1 2020.
- Funds reported $2.4B of Turning Point Therapeutics, Inc. Common Stock stock for Q2 2020, up 80% quarter-over-quarter.
- 49 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q2 2020 and 10 closed out, a net change of +39 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q2 2020 was Fidelity Investments, an estimated $45M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q2 2020 was Cormorant Asset Management, an estimated $18.4M sold.
Based on aggregated 13F filings for Q2 2020.